Drug and Therapeutics Committee – Minutes – Confirmed

Date / Time	Thursday 8th November 2018 8:15am – 9:30am
Venue	The Committee Room, Alderson House, HRI
Chair	Prof A Morice, Chair, Professor of Respiratory Medicine
Notes / Action Points	Mrs W Hornsby, Senior Pharmacy Technician
Quorate: Yes / No	Yes
Attendance	Miss J Morgan, Senior Pharmacist, Medicines Information Neurology and Stroke Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics Mr K McCorry, Medicines Optimisation Pharmacist, NECS (via speakerphone) Dr S Raise, GP ER CCG (via speakerphone) Dr A Samson, Infectious Diseases Consultant Prof M Lind, Vice Chair, Professor of Oncology Dr F Umerah, Consultant Anaesthetist Dr H Klonin, Consultant Paediatrician Dr O Ogunbambi, Consultant Rheumatologist Mr R Kapur, Vascular Surgeon
Apologies	Mr P O'Brien, Deputy Chief Pharmacist Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.11.01	**Apologies**	As above.					
2018.11.02	**Declarations of Interest**	None					11./18
2018.11.03	**Minutes of the previous meeting**	Accepted as a true record					11/18
2018.11.04	**Action Tracker**	**Fendix Media Advertising Campaigns on Pattie** DC has spoken to web services re advertising campaigns	Action complete		DC		11/18
		Tracker ML to submit application for Atezolizumab TA520	Ongoing		ML	8/18	
		New Process for Oncology Requests Review form and process in six months	Ongoing		SS/SG	1/19	
		New Process for Oncology Requests POB to discuss amendments to form with SS	Ongoing		POB	11/18	
		NICE Guidance ML to request Atezolizumab TA525	Ongoing		ML	8/18	
		NICE Guidance WH has added Midostaurin and Arsenic Trioxide to formulary	Action complete		WH		11/18
		E Cigs Vapes Stop smoking paper was circulated to committee members. PGD has now been updated so that treatment can be continued by community once patient discharged from HEY. Vapes are commissioned in Hull CCG not by East Riding.	Action complete		POB		11/18
		AOB – Out of Hours Flowchart DC has discussed with Medical Directors and will discuss with CS HG	Ongoing	DC to discuss with CS HG	DC	11/18	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		NICE Guidance ML to request application for Atezolizumab in line with NICE TA492	Ongoing		ML	9/18	
		NICE Guidance ML to request application for Niraparib in line with NICE TA528	Ongoing		ML	9/18	
		NICE Guidance WH has added Niraparib to back of formulary	Action complete		WH		11/18
		MHRA DSU JM is still preparing information for Pattie to advertise yellow card scheme	Ongoing		DC	11/18	
		NICE Guidance TA535 Lenvatanib has been added to back of formulary	Action complete		WH		11/18
		NICE Guidance TA538 Dinutuximab has been added to back of formulary with the note “not commissioned for use in children at HEY”	Action complete		WH		11/18
		NICE Guidance TA539 Lutetium ML to request application	Ongoing		ML	10/18	
		MHRA DSU August 18 KMc informed the committee that the practice teams have been tasked with checking prescribing figures for Esmya.	Action complete		KMc		11/18
		New Product Requests – Pentosan Licensed Product WH has added to formulary and also to HERPC agenda	Action complete		WH		11/18
		New Product Requests AM has written to applicants and WH has updated the formulary unlicensed list	Action complete		AM/ WH		11/18
		New Product Requests JM told the committee that POB has confirmed HEY were involved in three Erenumab trials. A new process is in place to	Action complete		POB		11/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		ensure that erroneous information is not supplied again. KMc informed the committee the CCGs will not commission Erenumab yet as they wish to wait for publication of NICE. DC asked the reasoning behind this decision and KMc explained that the decision was made in line with RMOC guidance on FOC. There was further discussion around the interpretation of the RMOC guidance and it was agreed to add to Dec agenda for further discussion. The committee felt that delaying treatment was a missed opportunity for treating patients with a FOC medicine that the committee have already approved for use. **Guidelines** ML has discussed guidelines for prevention and management of the infection in adult neutropenic patients with chemotherapy patients Hull CCG commissioning decision on AREDs and Lidocaine Plasters, which is now in line with ER CCG Due to Hull CCG recent commissioning decision the committee felt that clarity was required with regards to HEY prescribing these two products. AM would write to the Ophthalmologists and Pain Team to seek their views and a way forward.	Further discussion needed Action complete Clarity for HEY prescribers required	DC to request opinion of medical directors and HEY commissioning team WH to add to Dec agenda AM to write to both departments	DC WH ML AM	12/18 12/18 12/18	11/18
2018.11.05	**New Product Requests**	**Dalbavancin (Xydalba®)- Acute Bacterial Skin & Skin Structure Infections – Dr G Barlow** Trial information presented demonstrated that Dalbavancin is non inferior to other agents. The agent has the advantage of once/twice only administration which enables outpatient administration. For ID consultant use only following bedside review and discussion with a second ID consultant. **Collagenase Clostridium Histolyticum (Xiapex®) – Dupuytrens Contracture – Mr Chris Milner** The product has NICE approval TA459. **Levosert® - IUD – Mr A Oboh**	Approved Approved Approved	AM to write to applicants and WH to update formulary	AM WH	12/18	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		JM had prepared a comparison table of current IUD available and the committee approved use for licensed indication **Alectinib – ALK positive advanced NSCLC- Vicki Brown** Approved in line with TA536	 Approved				
2018.11.06	**NICE Guidance**	**NG107 Renal replacement therapy and conservative management** All medicines on formulary **NG108 Decision-making and mental capacity** No specific mention of medicines **TA542 Cabozantinib for untreated advanced renal cell carcinoma** On CDF **TA543 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs** On formulary **TA544 Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma** On CDF list **NG95 Lyme disease** Updated guidance all antibiotics on formulary	Noted Noted Noted WH to alter formulary entry to read “in line with NICE” Noted Noted				
2018.11.07	**MHRA Drug Safety Update**	Rivaroxaban (Xarelto▼) after transcatheter aortic valve replacement:increase in mortality, thromboembolic and bleeding events in patients in a clinical trial Ritonavir-containg products:reports of interactions with levothyroxine leading to reduced thyroxine levels Ponatinib (Iclusig▼):reports of posterior reversible	Noted Noted Noted				

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		encephalopathy syndrome Transdermal Fentanyl Patches: Life threatening and fatal opioid accidental exposure, particularly in children	 Noted				
2018.11.11	**Minutes from SMPC**	October 2018 DC was not in attendance at this meeting but gave a briefing of items discussed. Injectables policy in theatres Use of multidose vials for Mantoux BCG due to shortages has been risk assessed and approved Audit carried out on use of Dalteparin in maternity Unlicensed medicines work is ongoing A request to stock Adiphos on ITU had been made but was declined after a risk assessment was performed HK informed the committee that there had been issues recording a patients allergy reaction to ceftazidime on Lorenzo	Noted DC will discuss with Lorenzo pharmacist		DC	12/18	11/18
2018.11.11	**Minutes from HERPC**	None					11/18
2018.11.12	**Correspondence Received**	None					11/18
2018.11.13	**Regional Medicines Optimisation Committee**	Adalimumab update DC informed the committee that pharmacy have been working towards introduction of generic product. Patient leaflets have been approved and contract will begin 1/12/18. It was felt that the pathway will not initially be affected but may need updating in future. There will be more than one option of brand including a citrate free option	Noted	No further action			11/1/8
2018.11.14	**Chairs approvals**	None					11/18
2018.11.15	**Issues to escalate to OQC**	None					11/18

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2018.11 16	**Any Other Business**	MHRA Alert Radium 223 Dichloride – new restrictions on use ML informed the committee that there had been a large increase in the number of patients requesting cannabis oils, and asked if any work had begun in this area. The use of cannabis oils for patient treatment became legal on 1/11/18 however there is not a licensed form available for patients as yet. A special is available from a company in the Netherlands and there is a compassionate use scheme available for an FDA licensed product made in the US. The committee understands that NICE are looking at the use of cannabis oil in the following three areas Pain, Chemotherapy induced nausea and vomiting and Paediatric Epilepsy with a view to reviewing use in MS later on . As yet the committee have not received an application for the product and there have been no chairs approval requests. JM informed the committee that Sheffield are using the compassionate use scheme with the US product to treat epilepsy in paediatric patients. FU asked for an update on the tinzaparin dalteparin switch. DC informed the committee that the switch had taken place due to manufacturing issues with dalteparin. The switch at CHH had run smoothly and the switch at HRI had taken place on Wed with a few more issues. Day Surgery patients and maternity patients would still receive prophylactic treatment with dalteparin. Only prophylaxis patients have been transferred to tinzaparin treatment patients would still receive dalteparin. KMc informed the committee that as yet no problems had been reported in the community and this issue would be further discussed at the MMIG meeting next week.	AM to write to main users of product To ask paediatrics to fill in new product request for Epidolex	 JM	AM	12/18	
2018.11 17	**Date and Time of**	Thursday 13th December – 8.15 – 9.30am, The Board Room,					

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
	Next Meeting	Alderson House, HRI.					